Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design

BACKGROUND: Following universal recommendation for use of 13-valent pneumococcal conjugate vaccine (PCV13) in US adults aged ≥65 years in September 2014, we conducted the first real-world evaluation of PCV13 vaccine effectiveness (VE) against hospitalized vaccine-type community-acquired pneumonia (C...

Descripción completa

Detalles Bibliográficos
Autores principales: McLaughlin, John M, Jiang, Qin, Isturiz, Raul E, Sings, Heather L, Swerdlow, David L, Gessner, Bradford D, Carrico, Ruth M, Peyrani, Paula, Wiemken, Timothy L, Mattingly, William A, Ramirez, Julio A, Jodar, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206101/
https://www.ncbi.nlm.nih.gov/pubmed/29790925
http://dx.doi.org/10.1093/cid/ciy312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206101/
https://www.ncbi.nlm.nih.gov/pubmed/29790925
http://dx.doi.org/10.1093/cid/ciy312

Ejemplares similares